SCHEMBL8234613

SCHEMBL8234613

CSC(=O)C(C)C(=O)c1ccc(CC(N)C(=O)O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 5/20 0.51
▸ TPH1 P17752 2/20 0.51
▸ PTGS1 P23219 3/20 0.50
▸ ALPI P09923 1/20 0.50
▸ PKM P14618 1/20 0.50
▸ XIAP P98170 1/20 0.50
▸ HIF1A Q16665 5/20 0.46
▸ CYP3A4 P08684 3/20 0.46
▸ ALOX15 P16050 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ ABCB11 O95342 1/20 0.46
▸ CHRM2 P08172 1/20 0.46
▸ ADRA2A P08913 1/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ ACHE P22303 1/20 0.46
▸ OPRM1 P35372 1/20 0.46
▸ DRD3 P35462 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12337990 0.86 SLC7A5 (0.59) SLC7A5TPH1PTGS1ALPIPKM
SCHEMBL8237673 0.81 SLC7A5 (0.53) SLC7A5TPH1PTGS1ALPIPKM
SCHEMBL13703211 0.80 SLC7A5 (0.51) SLC7A5TPH1PTGS1ALPIPKM
SCHEMBL8237017 0.78 SLC7A5 (0.53) SLC7A5TPH1PTGS1ALPIPKM
SCHEMBL12029164 0.77 TPH1 (0.48) SLC7A5TPH1PTGS1ALPIPKM
SCHEMBL6777440 0.76 SLC7A5 (0.67) SLC7A5TPH1PTGS1ALPIPKM
SCHEMBL93537 0.76 SLC7A5 (0.67) SLC7A5TPH1PTGS1ALPIPKM
SCHEMBL93538 0.76 SLC7A5 (0.67) SLC7A5TPH1PTGS1ALPIPKM
SCHEMBL2310526 0.76 SLC7A5 (0.83) SLC7A5TPH1PTGS1ALPIPKM
SCHEMBL25386077 0.75 SLC7A5 (0.61) SLC7A5TPH1PTGS1ALPIPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037405-B2 Anti-CD70 antibody drug conjugates AMBRX, INC. 2024-07-16 — — US disclosed
US-12037405-B2 Anti-CD70 antibody drug conjugates AMBRX, INC. 2024-07-16 — — US disclosed
US-20230295320-A1 Anti-CD70 Antibody Drug Conjugates AMBRX, INC. (US) 2023-09-21 — — US disclosed
US-20230295320-A1 Anti-CD70 Antibody Drug Conjugates AMBRX, INC. (US) 2023-09-21 — — US disclosed
US-20220411469-A1 COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES AMBRX, INC. (US) 2022-12-29 — — US disclosed
US-20220033518-A1 PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES AMBRX,INC. (US) 2022-02-03 — — US disclosed
EP-3170821-B1 COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES AMBRX INC (US) 2021-09-15 — — EP disclosed
US-20210277056-A1 COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES AMBRX, INC. (US) 2021-09-09 — — US disclosed
US-10954270-B2 Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives AMBRX, INC. (US) 2021-03-23 — — US disclosed
US-10800856-B2 Prostate-specific membrane antigen antibody drug conjugates AMBRX, INC. (US) 2020-10-13 — — US disclosed
US-20150152190-A1 Prostate-Specific Membrane Antigen Antibody Drug Conjugates AMBRX, INC. (US) 2015-06-04 — — US disclosed
US-20150141624-A1 Anti-CD70 Antibody Drug Conjugates AMBRX, INC. (US) 2015-05-21 — — US disclosed
US-20150141624-A1 Anti-CD70 Antibody Drug Conjugates AMBRX, INC. (US) 2015-05-21 — — US disclosed
US-20150080559-A1 Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives AMBRX, INC. (US) 2015-03-19 — — US disclosed
US-20150080559-A1 Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives AMBRX, INC. (US) 2015-03-19 — — US disclosed
WO-2012166560-A1 COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES AMBRX, INC. (US) 2012-12-06 — — WO disclosed
WO-2012166559-A1 COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES AMBRX, INC. (US) 2012-12-06 — — WO disclosed
US-20090240029-A1 Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides AMBRX, INC. (US) 2009-09-24 — — US disclosed
US-20090240029-A1 Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides AMBRX, INC. (US) 2009-09-24 — — US disclosed
WO-2007079130-A2 COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES AMBRX, INC. (US) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411469-A1 COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES DDOST, DAD1, PTMS SLC7A5 127/4885TPH1 2441/4885PTGS1 1295/4885
US-12037405-B2 Anti-CD70 antibody drug conjugates CD74, CD63, CD47 SLC7A5 264/4885TPH1 4103/4885PTGS1 4544/4885
US-20150141624-A1 Anti-CD70 Antibody Drug Conjugates CD74, CD63, CD47 SLC7A5 264/4885TPH1 4103/4885PTGS1 4544/4885
US-10800856-B2 Prostate-specific membrane antigen antibody drug conjugates KLK3, PTMS, DDOST SLC7A5 545/4885TPH1 4139/4885PTGS1 1909/4885
US-20210277056-A1 COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES DDOST, DAD1, PTMS SLC7A5 127/4885TPH1 2441/4885PTGS1 1295/4885
US-10954270-B2 Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives DDOST, DAD1, PTMS SLC7A5 127/4885TPH1 2441/4885PTGS1 1295/4885
US-20230295320-A1 Anti-CD70 Antibody Drug Conjugates CD63, CD74, CD99 SLC7A5 221/4885TPH1 3731/4885PTGS1 4492/4885
US-20220033518-A1 PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES KLK3, PTMS, DDOST SLC7A5 545/4885TPH1 4139/4885PTGS1 1909/4885
US-20150152190-A1 Prostate-Specific Membrane Antigen Antibody Drug Conjugates KLK3, PTMS, DDOST SLC7A5 545/4885TPH1 4139/4885PTGS1 1909/4885
US-20090240029-A1 Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides DNPEP, DDC, PTMS SLC7A5 409/4885TPH1 3747/4885PTGS1 3564/4885
US-20150080559-A1 Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives DDOST, DAD1, PTMS SLC7A5 132/4885TPH1 2461/4885PTGS1 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback